Perspectives: Pharma, the next Brexit drama?

Share with
Tweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Buffer this pageEmail this to someone
Luke Sewell
Multilingual January/February 2017
Columns and Commentary

In reality, the future is still bright both for the UK pharmaceutical and language service market despite the mid-term uncertainties. The UK is home to four of the top ten global universities even though the UK represents just 0.16% of global land mass. 20% of the world’s biggest selling drugs were developed in the UK. The UK is home to the fifth and sixth largest pharmaceutical companies in the world — all underpinned by a strong economy, legal structure and international language....

The EU has some heavy pharmaceutical and medicine regulation, including the cumbersome clinical trials directive, conducting a clinical trial has since become prohibitively expensive allowing access only to large pharmaceutical companies and squeezing out academic research or small and medium-sized business. At its most extreme, according to The Pharmaceutical Journal the decision to overregulate the biotechnology sector has led one firm to relocate to the United States.

Despite aspects to be quietly positive about, the Association of the British Pharmaceutical Industry did voice its concerns following the vote, citing “immediate challenges for future investment, research and jobs.” Following the vote they also cite that the UK “runs the risk of losing its attractiveness first-tier launch to market” as well as suffering the relocation of the aforementioned EMA and the pharmacovigilance operations for many pharma companies currently in the UK.

It is not just industry voicing concerns....


Share with
Tweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Buffer this pageEmail this to someone